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ABSTRACT
Rectal cancer represents approximately 10% of cancers worldwide. Preoperative 
chemoradiotherapy increases complete pathologic response and local control, 
although it offers a poor advantage in survivorship and sphincter saving compared 
with that of radiotherapy alone. After preoperative chemoradiotherapy, approximately 
20% of patients with rectal cancer achieve a pathologic complete response to the 
removed surgical specimen; this response may be related to a better prognosis and an 
improvement in disease-free survival. However, better biomarkers to predict response 
and new targets are needed to stratify patients and obtain better response rates.
MAP17 (PDZK1IP1) is a small, 17 kDa non-glycosylated membrane protein 
located in the plasma membrane and Golgi apparatus and is overexpressed in a wide 
variety of human carcinomas. MAP17 has been proposed as a predictive biomarker 
for reactive oxygen species, ROS, inducing treatments in cervical tumors or laryngeal 
carcinoma. Due to the increase in ROS, MAP17 is also associated with the marker 
of DNA damage, phosphoH2AX (pH2AX). In the present manuscript, we examined 
the values of MAP17 and pH2AX as surrogate biomarkers of the response in rectal 
tumors. MAP17 expression after preoperative chemoradiotherapy is able to predict 
the response to chemoradiotherapy, similar to the increase in pH2AX. Furthermore, 
we explored whether we can identify molecular targeted therapies that could help 
improve the response of these tumors to radiotherapy. In this sense, we found that 
the inhibition of DNA damage with olaparib increased the response to radio- and 
chemotherapy, specifically in tumors with high levels of pH2AX and MAP17.
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INTRODUCTION
Rectal cancer represents approximately 10% of 
cancers worldwide [1]. In 2012, there were 446.801 
newly diagnosed cases and 214.727 deaths attributed to 
this entity in Europe [1]. Colorectal cancer was estimated 
to be the most frequent neoplasm diagnosed in Spain in 
2015 [2]. The standard of care in patients with locally 
advanced rectal cancer is preoperative chemoradiotherapy 
before surgical excision. The addition of preoperative 
radiation therapy improves local control and survival in 
this set of patients [3–8]. Preoperative chemoradiotherapy 
increases the complete pathologic response and local 
control, although it offers a poor advantage in survivorship 
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and sphincter saving compared with that of radiotherapy 
alone [9–13]. After preoperative chemoradiotherapy, 
approximately 20% of patients with rectal cancer achieve 
a pathologic complete response in the surgical specimen 
removed, which may be related with a better prognosis and 
an improvement in disease-free survival [14]. However, 
better biomarkers to predict response and new targets are 
needed to stratify patients and to obtain better response 
rates.
MAP17 is a small, 17 kDa non-glycosylated 
membrane protein located in the plasma membrane and 
Golgi apparatus [15]. Although its physiological role is not 
fully clear, different studies have shown that it stimulates 
sodium-glucose linked transporter (SGLT), thereby 
increasing glucose and mannose uptake in Xenopus 
ovocites [15] and human tumor cells [16].
MAP17 is overexpressed in a wide variety of 
human carcinomas [16]. According to a study by 
Guijarro et al. [16] on carcinoma tumor samples from 
different localizations, MAP17 overexpression is >70% 
in the ovary, colon, stomach, cervix and thyroid gland 
and approximately 50% in the lung, uterus and rectum. 
Furthermore, overexpression of the protein strongly 
correlates with tumor progression in colon, prostate, 
sarcomas and ovarian carcinomas (P < 0.0001) [16]. 
Tumor cells that overexpress MAP17 show 
phenotypic advantages with enhanced proliferative 
capabilities, decreased apoptotic sensitivity and increased 
migration [17]. The mechanism responsible for the 
increased tumor capabilities of cells expressing MAP17 
has not yet been described. MAP17 overexpression in vitro 
activates the Notch pathway in tumor cells, leading to an 
increase in the stem cell pool [18]. This aberrant signaling 
activation may be present in a large percentage of tumors 
[18]. A correlation between MAP17 expression and an 
inflammatory phenotype in tumors and other inflammatory 
diseases has also been described. Immunohistochemical 
analysis has confirmed local inflammation, even at 
the site of MAP17 expression in tumors [19]. Chronic 
inflammation is also a cause of neoplastic transformation 
and progression; therefore, it is likely that MAP17 plays 
an important role in cancer development by regulating the 
immune microenvironment [19]. 
This increased malignant behavior is associated 
with an increase in reactive oxygen species (ROS) 
production, and treatment of cells with antioxidants 
reduces their tumorigenic properties [17]. ROS play a 
fundamental role in cellular physiology. They promote 
both cell proliferation and growth and cell death, which 
is a highly efficacious tool in cancer treatment. This dual 
mechanism has been related with ROS concentrations in 
the cellular environment. At low levels, they are involved 
in maintaining cellular homeostasis and regulate cellular 
physiological processes such as proliferation and apoptosis 
[20]. When the concentration of ROS increases, they act 
as oncogene activators [21] and as intracellular second 
messengers for proliferation and cell growth [22, 23]. 
However, further increases in ROS (close to threshold 
levels) may induce a toxic environment and turn the 
physiology of cells towards apoptosis [24, 25].
The ectopic expression of MAP17 increases glucose 
and mannose uptake, generating an increase in ROS levels 
as a product of increased metabolism [17]. A direct link 
between MAP17 and the terminal domain of glucose 
transporters is also possible, altering ion exchanges and 
the intracellular redox-balance [26]. Tumors expressing 
high levels of MAP17 may benefit from therapies that 
increase oxidative stress. These tumors show increased 
ROS production and could cross the threshold toxic level 
easier than non-tumor cells with oxidative treatments [26], 
which has been observed in tumor types subjected to ROS-
inducing treatments.
MAP17 expression was detected in approximately 
70% of tumors from more than 200 cervical tumor 
samples obtained from biopsies prior to treatment. After 
treatment with cisplatin plus radiotherapy, high levels of 
MAP17 were related with improved patient survival [27]. 
Therefore, high levels of MAP17 could serve as a marker 
for good prognosis in patients with cervical tumors after 
cisplatin plus radiotherapy treatment [27]. 
Similarly, MAP17 has also been proposed as a 
predictive biomarker for laryngeal carcinoma. Patients 
with larynx cancer and high MAP17 expression in 
pretreatment biopsies showed better outcomes than those 
with low MAP17 expression [28]. MAP17 expression 
was associated with overall survival (OS) (p < 0.001), 
laryngoesophageal dysfunction-free survival (p = 0.002) 
and locoregional control (p = 0.016) [28]. The same study 
found a positive correlation between MAP17 expression 
and SGLT (p = 0.022) and high levels of MAP17/SGLT 
in combination with an increase in OS (p = 0,028) [28]. 
MAP17 is also associated with the marker of DNA 
damage, phosphoH2AX (pH2AX). When pH2AX was 
evaluated in combination with MAP17, higher expression 
of both potential biomarkers was associated with an 
improvement in laryngoesophageal dysfunction-free 
survival (61.35 vs. 32.2 months, p = 0.05) and OS (66.6 
vs 39.8 months, p = 0.01) [29]. In tumors with MAP17 
overexpression, pH2AX, which acts as a surrogate of 
tumor damage, could be induced by an increase in ROS. 
[29] Histone H2AX is a variant of histone H2A and is 
implicated in DNA repair. H2AX becomes phosphorylated 
in response to DNA double-strand breaks and is then 
called gamma-H2AX (γH2AX or pH2AX), which 
participates in the recruitment of DNA repair proteins; it 
can be phosphorylated by kinases of the PI3-family, such 
as ataxia telangiectasia mutated (ATM) and ATMRad3- 
related (ATR), in response to DNA damage. pH2AX has 
been employed as an indicator of unrepaired DNA damage 
and has been proposed as a sensitive marker of cancer 
progression and response to cancer therapies [30].
In the present study, we investigated whether 
MAP17 and pH2AX expression levels can be detected 
in locally advanced rectal cancer after preoperative 
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chemoradiotherapy and their relationship with disease-free 
survival (DFS) and OS prognostic values. Furthermore, 
we explored whether we can identify molecular targeted 
therapies that could help improve the response of these 
tumors to radiotherapy.
RESULTS
MAP17 expression in rectal tumor samples
Our cohort of 135 samples from patients with 
locally advanced rectal cancer who received preoperative 
chemoradiotherapy in the same institution from 2005 to 
2014 (Supplementary Table 1) was evaluated for OS for 
comparison with published data. In our cohort, we found 
a 5-year OS of 75% (Figure 1A), which is similar to other 
published cohorts [31, 32].
Positive MAP17 expression was evaluated by 
immunohistochemistry (Figure 1B). Increased MAP17 
protein expression in the tumor samples was defined to 
occur when the percentage of stained tumor was higher 
than 0.75 (0–3, as indicated in the M&M) compared to 
that of non-tumor samples [27, 28], and low expression 
was defined by a value lower or equal to 0.75. Under 
these conditions, 93 (69%) tumor samples exhibited 
high expression of MAP17 and 42 (31%) exhibited low 
expression (Figure 1C). Similar data were obtained when 
the mRNA was analyzed in publicly accessible databases, 
such as the Kaiser colon [33] through the Oncomine 
analysis portal (Figure 1D). The analysis of our cohort 
also revealed that the levels of MAP17 were associated 
with the development of metastases (p = 0.07). Although it 
does not reach statistical significance, shows a clear trend 
(Figure 1E). 
MAP17 expression and prognostic values
Patients with low MAP17 expression also showed a 
better OS (p = 0.064) and DFS (p = 0.380) compared with 
those with high expression (Figure 2A and 2B). Although 
these data do not reach statistical significance, they show 
a clear trend, individuals with higher levels of MAP17 are 
at a higher risk and show a worse response to anticancer 
treatments (Figure 2C and 2D) than those with lower levels 
of MAP17. 
Since MAP17 levels were associated with 
metastases, we analyzed whether MAP17 is linked to 
this phenotype or whether its diagnostic capability is 
independent of the metastases and analyzed its survival 
probability. Patients with metastases and high MAP17 
levels showed worse survival probability than those with 
low MAP17 levels (p = 0.7) (Figure 2E) Although it does 
not reach statistical significance, shows a clear trend. 
Therefore, MAP17 is an independent prognostic factor of 
metastases. 
Pathways enriched in genes correlating with 
MAP17 expression in rectal tumors
Next, we used the R2 bioinformatics platform 
to analyze genes and pathways that may be associated 
with MAP17 expression in rectal tumors. Altered genes 
associated with MAP17 expression were mainly related 
with DNA damage and DNA repair functions (Figure 3). 
These genes were also related with signal transduction, 
membrane proteins, drug targets and development. 
Among the genes related to DNA damage and DNA 
repair functions, we found genes involved in the Fanconi 
anemia pathway (27%) homologous recombination (27%), 
nucleotide excision repair (20%), base excision repair 
(16%) and mismatch repair (10%).
Phosphorylation of H2AX (pH2AX) in rectal 
tumor samples
Positive pH2AX expression was 
immunohistochemically examined by double-blind 
independent observations (Figure 4A). We detected 
increased pH2AX protein expression in some tumor 
samples compared to that in non-tumor samples (Figure 
4A). The levels of pH2AX expression were scored by 
multiplying the strength of nuclear staining (0–3) and the 
percentage of tumor cells with positive nuclei. The cut-
off point was considered 100 (<100 as negative, >100 as 
positive) [29]. Under these conditions, 82 (60%) tumor 
samples exhibited high expression of pH2AX and 53 
(40%) exhibited low expression (Figure 4B).
Low expression of pH2AX was associated with 
a better prognosis in terms of OS (p = 0.156), although 
this result was not statistically significant (Figure 4C). 
However, low pH2AX expression was not associated with 
DFS (p = 0.659) (Figure 4D).
When combining pH2AX and MAP17 expression, 
patients with low marker values of both proteins (pH2AX 
expression < 100 and MAP17 expression ≤ 0.75) obtained 
better DFS (p = 0.188) and OS (p = 0.037) than those with 
high values (pH2AX ≥100 and MAP17 >0.75) (Figure 5).
The DNA damage inhibitor olaparib re-sensitizes 
MAP17- and pH2AX-positive rectal tumors to 
radiotherapy
It is clear that patients with tumors exhibiting 
high levels of both MAP17 and pH2AX have a worse 
prognosis. These results may be related to an increase in 
the DNA damage response associated with MAP17. It is 
possible to increase the sensitivity to radiotherapy in these 
MAP17+pH2AX tumors by inhibiting the response to 
DNA damage (DDR). This point has been shown in other 
contexts [34–36] but not in the context of radiotherapy-
treated operable locally advanced rectal cancer. 
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Figure 1: MAP17 upregulation in rectal tumors after concurrent chemoradiotherapy. (A) Overall survival analysis of the 
rectal tumor cohort (Supplementary Table 1) used in this study. (B) Representative pictures of MAP17-stained rectal tumor samples. An 
ROC curve was used to identify the cut-off point (0.75). (C) Percentage of tumors positive and negative for MAP17 in our cohort of rectal 
tumor samples (n = 135). (D) MAP17 mRNA expression levels in non-tumor colon (n = 5) and rectal mucinous adenocarcinomas (n = 4). 
(E) MAP17 mRNA expression levels in samples from patients without metastasis (NO) vs patients with metastasis (YES).
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Figure 2: Prognosis analysis of MAP17 expression in rectal tumors after concurrent chemoradiotherapy. (A, B) 
Association between MAP17 protein expression assessed by IHC to survival in the rectal tumor cohort. (A) Overall survival (OS) and (B) 
disease-free survival (DFS) Kaplan-Meier survival curves based on MAP17 protein expression. (C) mRNA MAP17 expression by risk 
group in TCGA rectal tumors cohort. (D) mRNA MAP17 expression by responders or non-responders in TCGA rectal tumors cohort. (E) 
Kaplan–Meier accumulated survival curve according to time to metastasis by MAP17 mRNA expression.
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To prove this point, we explored the levels of MAP17 
and pH2AX in a panel of colorectal cell lines (Figure 6A, 6B, 
Supplementary Table 1). We selected 2 colorectal cell lines, 
HCT116 with high MAP17 and high pH2AX expression, 
and SW480, with low MAP17 and pH2AX expression 
(Figure 6A, 6B). These lines were treated with different 
doses of radiotherapy either in the presence or absence of the 
PARP inhibitor olaparib (Figure 6C, 6D). The suboptimal 
dose selected (10 µM) does not induce any significant 
decrease in survival. Radiation of 2 Gy alone induced a 
clear decrease in survival in the HCT116 cell line, which 
was more pronounced in the presence of olaparib (Figure 
6C, 6D). At 4 Gy of radiotherapy treatment, we observed 
a further decrease in survival that was more pronounced in 
the presence of olaparib. These data indicate that treatment 
with suboptimal doses of olaparib prior to radiation 
treatment may decrease the survival of MAP17+pH2AX-
positive tumors (Figure 6C). However, these results are 
not maintained in SW480, a cell line with low levels of 
these markers. In this case, olaparib does not induce a 
further decrease in survival induced by radiotherapy alone 
(Figure 6F).
Since radiotherapy treatment of rectal tumors is 
concurrent with chemotherapy, which usually involves 
5FU, we determined whether the inhibition of DNA 
repair by olaparib improves chemotherapy treatment in 
rectal tumors when applied as concurrent chemotherapy. 
Both cell lines were treated with different doses of 
chemotherapy either in the presence or absence of 
suboptimal doses of olaparib (10 µM) (Figure 6E, 6F). 
Olaparib treatment did not sensitize SW480 cells, the 
line with low MAP17 and low pH2AX expression, to 
5FU treatment (Figure 6E). However, in the HCT116 cell 
line with high levels of MAP17 and pH2AX, treatment 
with suboptimal doses of olaparib caused a significant 
reduction in the IC50 value of 5FU (Figure 6F). 
DISCUSSION
The use of long-course chemoradiation (CRT) or 
concurrent short-course radiotherapy (SCRT) consistently 
improves local control rates compared to those from 
surgery alone, postoperative CRT or postoperative 
radiotherapy [37, 38]. However, its use does not 
consistently translate to OS [39].
Therefore, multidisciplinary information has 
become important when making decisions regarding 
CRT. These decisions are based on the combination of 
magnetic resonance imaging (MRI), tumor and patient 
characteristics and laboratory experimental findings.
Very few robust molecular studies have elucidated 
the mechanism of chemoradiation resistance. Very few 
promising predictive biomarkers have been suggested, 
including EGFR, thymidylate synthase, PI3K, methylation 
or proteins involved in the ras/MAPK pathway [40–44]. 
Furthermore, it has been reported that different genomic 
signatures identify responders and non-responders from 
whole-genome analysis [39, 42]. However, none of the 
signatures from the gene microarray profile on locally 
advanced rectal cancer have been successfully validated 
as a diagnostic or prognostic tool applicable to routine 
clinical practice [39]. 
Figure 3: Gene Ontology pathways correlating with MAP17 expression. Genes that correlated with MAP17 expression 
(Pearson r < −0.35, r > 0.35) were selected. Gene Ontology analysis was applied, and the most representative signaling pathways are 
presented.
Oncotarget32964www.oncotarget.com
Our work shows that patients with high MAP17 are 
associated with worse OS and the presence of metastasis. 
Furthermore, the associated high levels of MAP17 
and pH2AX showed better prognostic capability than 
MAP17 or pH2AX alone. The fact that the combination 
of MAP17 and pH2AX has better prognostic capability in 
rectal tumors is consistent with others in laryngeal cancer 
in which high levels of MAP17 (and to a greater extent, 
Figure 4: Phosphorylation of γH2AX (p-H2AX) in rectal tumors after concurrent chemoradiotherapy. (A) Representative 
pictures of MAP17-stained rectal tumor samples. (B) Percentage of tumors positive and negative for MAP17 in our cohort of rectal tumor 
samples (n = 135). An ROC curve was used to identify the cut-off point (100). (C) Overall survival (left) and disease-free survival (right) 
analysis of the rectal tumor cohort (Supplementary Table 1) used in this study. (D) Disease-free survival analysis of the rectal tumor cohort 
(Supplementary Table 1) used in this study
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high MAP17 and high pH2AX) correlated with improved 
patient survival after treatment [28, 45, 46]. 
In this setting, our analysis in rectal cancer showed 
a clear but not statistically significant relationship 
between low MAP17 protein expression and increased 
OS, suggesting that MAP17 expression is an independent 
biomarker for survival. In fact, high MAP17 levels 
demonstrated worse OS than low levels. 
pH2AX was also related with OS in the same 
cohort of 135 patients with rectal cancer. Our data suggest 
that inherent DDR pathway activation (measured by 
the endpoint of γH2AX phosphorylation) is a valuable 
prognostic marker in patients with rectal carcinoma who 
received radiation therapy. 
It has been proposed that the DDR network may 
serve as an inducible barrier to control the initial steps 
of tumor development by inducing p53-dependent 
senescence or apoptosis [46–49]. Ongoing chronic DDR 
activation favors the outgrowth of malignant clones with 
genetic or epigenetic defects in a DNA repair mechanism, 
such as those involved in the DDR pathway [49]. Our 
samples from already malignant tumors (stages II-IV) 
correlated with a worse onset of disease. It is likely that 
DNA damage defects that induce DDR activation are 
carried through the malignant process and it is possible 
that other proteins are mutated in the process, resulting in 
the DNA-damaging effect of radiotherapy.
We also showed that the combination of MAP17 and 
pH2AX has a predictive role in patients with rectal cancer 
treated with CRT. Taking into account the combined 
analysis of pH2AX and MAP17, we hypothesize that the 
DDR pathway plays an essential role in the predictive 
outcome of rectal cancer. Furthermore, proof of concept 
analysis of tumor cells treated with olaparib indicated 
that DNA repair pathway inhibition sensitizes tumor cells 
with high MAP17 and pH2AX levels to radiotherapy and 
concurrent chemotherapy.
High MAP17 levels are associated with OS. MAP17 
increases endogenous ROS [26, 27, 50], which induce 
DNA damage [51]. Data from our study and others suggest 
that high levels of MAP17 induce ROS, which increase 
DNA damage and DDR signaling; this is denoted by 
higher pH2AX levels [45, 51]. Upon the inhibition of DNA 
damage or a further increase in damage by RT treatment, 
tumors are more likely to undergo apoptosis. Furthermore, 
proof of principle experiments in vitro demonstrated that 
DNA damage inhibitors such as olaparib increased the 
sensitivity of MAP17-expressing cells, confirming the 
relevance of the oxidative status of the tumors in response 
to radiation. Patients who are unlikely to respond could be 
offered an alternative approach to therapy by co-adjuvant 
or concurrent chemotherapy combined with inhibition of 
the DNA damage response pathway. 
Therefore, our data confirm that pH2AX (and its 
combination with MAP17) levels, is a marker of structural 
DNA damage in rectal tumors and thus may serve as a 
novel valuable and easily applicable predictive biomarker 
for rectal carcinoma.
In conclusion, current treatment depends on clinical 
and laboratory predictive and prognostic markers. Our 
study focused on the use of two predictive markers to 
explain some variability in response to standard treatment. 
Figure 5: Combined MAP17 and phosphorylation of γH2AX (p-H2AX) analysis of survival in rectal tumors after 
concurrent chemoradiotherapy. Overall survival (left) and disease-free survival (right) analysis of the rectal tumor cohort 
(Supplementary Table 1) used in this study. Cut-off points are the same as those listed above; high MAP17 (0 > 0.75), high pH2AX (> 100).
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MAP17 and pH2AX, either alone or in combination, levels 
obtained after RT and co-adjuvant therapy or concurrent 
chemotherapy treatment are predictive markers to predict 
the responses of rectal tumors. Furthermore, our work 
offers an adjusted therapy to patients with a combination 
of these biomarkers (high MAP17 + high pH2AX) by 
the addition of olaparib (or other DNA repair inhibitors 
+ RT treatment). In future trials, assessing CRT and 
neo-, coadjuvant or concurrent chemotherapy for rectal 
cancer should be evaluated prospectively. It is clear that 
Figure 6: The DNA damage inhibitor olaparib re-sensitizes MAP17- and pH2AX-positive rectal tumors to radiotherapy 
treatment. (A) Western blot analysis and relative quantification of the protein levels of phospho-γ-H2AX in colon tumor cell lines. (B) 
RT-qPCR showing the RNA levels of MAP17 in HCT116 and SW480 colon tumor cell lines. Samples were normalized to GAPDH. 
(C and D) Percentage of survival fraction after olaparid treatment (10 µM), radiology treatment (2 and 4 Gy) or their combination in 
HCT116 and SW480 colon tumor cell lines. (E and F) Determination of the IC50 value (concentration of the drug necessary to induce 50% 
cell death) for SW480 and HCT116 and colon tumor cells lines following treatment with olaparid and/or 5FU. 
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there is a biological basis to support the use of olaparib 
as a co-adjuvant or concurrent chemotherapy in patients 
with tumors with high MAP17+pH2AX and treated with 
radiation + 5FU, while patients with markers predicting 
a poor response could be offered an adjusted therapy in 
terms of agents or treatment sequence.
MATERIALS AND METHODS
Study approval
All patients provided written informed consent 
according to the protocol approved by the local ethics 
committee (CEI 0309-N-15). All tissue samples and 
patient information were treated according to the 
Declaration of Helsinki.
Cohort description and treatment
We evaluated tumor samples from 135 patients with 
locally advanced rectal cancer who received preoperative 
chemoradiotherapy in the same institution from 2005 to 
2014 (Supplementary Table 1). 
Eligibility criteria included patients with locally 
advanced rectal cancer T3-4 N+ M0 (stages II-III) who 
completed the neoadjuvant chemoradiotherapy plan 
before resection with curative intention. We excluded 
patients with synchronous metastases at diagnosis or 
with metastatic disease before treatment. The patients 
included 43 women and 92 men. The median diagnostic 
age was 68 years old. Fifty-four tumors were localized 
in the low rectum (3–5 cm from the anal verge), 45 were 
localized in the medium rectum (6–9 cm) and 34 were 
localized in the high rectum (10–15 cm). In two patients, 
the localization was not recorded in the medical history. 
Before induction treatment, 28 patients presented with 
tumors with a histological grade of 1, 67 presented with 
a grade of 2, 5 presented with a grade of 3 and, in 35 
patients, these data were missing. One patient presented 
with TNM stage I before neoadjuvant treatment and 
surgery, 23 presented with IIA stage, 3 patients presented 
with IIB stage, 10 patients presented with IIC stage, 7 
patients presented with IIIA stage, 67 patients presented 
with IIIB stage, 22 patients presented with IIIC stage, 
and 2 patients presented with stage IVa. All patients 
received the same neoadjuvant chemoradiotherapy 
treatment based on three-dimensional conformal radiation 
therapy (3D-CRT) achieving doses of 45–50.4 Gy with 
concurrent chemotherapy. Concurrent chemotherapy 
regimens included continuous infusion of 5-fluorouracil 
(225 mg/m2) over 24 hours 5 or 7 days/week or 
capecitabine (825 mg/m2) twice daily 5 days/week during 
radiation therapy. Most patients underwent surgery 4–6 
weeks after neoadjuvant treatment. 
Eighty-nine patients were managed with low 
anterior resection, 41 with abdominoperineal resection, 
and 5 with another procedure. After wound healing 
and overall recovery, most patients received adjuvant 
chemotherapy with XELOX (capecitabine plus 
oxaliplatin) or capecitabine monotherapy.
After a median follow-up of 45 months, 34 patients 
experienced tumor recurrence: 11 presented with local 
relapse, 7 presented with hepatic disease, 7 presented 
with lung disease, 2 presented with local relapse and 
synchronous hepatic metastases, 3 presented with local 
relapse and synchronous lung metastases, 1 presented 
with local relapse and peritoneal disease, and 3 presented 
with distant metastases in a different location. In the same 
period, 34 patients passed away. The mean OS was 91.99 
months (95% confidence interval [CI] 83.78–100.20) and 
the mean DFS was 81.96 months (95% CI 73.17–90.76).
Tissue acquirement and preparation
Formalin-fixed, paraffin-embedded tissue sections 
from 135 rectal tumors were selected. Histological 
characterization of all samples was assessed by 
hematoxylin and eosin staining. We constructed tissue 
microarrays (TMAs) with two representative samples of 
each tumor and 3 control samples of non-tumor rectal 
tissues. 
These tissue samples were solicited to the 
Andalusian Public Health System Biobank under the 
current normative, and all samples were owned by patients 
who expressed their agreement in writing for the donation 
and handling of the samples for scientific purposes.
Immunohistochemistry 
Three-micrometer slices were sectioned from the 
TMA block and applied to coated immunochemistry slides 
(DAKO, Glostrup, Denmark). The slides were baked 
overnight in a 56° C oven, deparaffinized in xylene for 
20 min, rehydrated through a graded ethanol series and 
washed with PBS. A heat-induced epitope retrieval step 
was performed by heating the slide in a solution of sodium 
citrate buffer (pH 6.5) for 2 min in a conventional pressure 
cooker. After heating, the slides were incubated with 
proteinase K for 10 min and rinsed in cool running water 
for 5 min. Endogenous peroxide activity was quenched 
with 1.5% hydrogen peroxide (DAKO) in methanol 
for 10 min. Incubation with the primary antibodies, 
anti-MAP17 (1:4) [29–33] and anti-phospho-g-H2AX 
(phospho S139)(ab11174 from Abcam), was performed for 
40 min. After incubation, immunodetection was performed 
with the EnVision (DAKO) visualization system using 
diaminobenzidine chromogen as the substrate according 
to the manufacturer’s instructions. Immunostaining was 
performed in a TechMate 500 automatic immunostaining 
device (DAKO) and measured through a double-
blind visual assessment using microscopic observation 
according to the anatomopathological experience of 
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the pathologists. Sample scoring was performed by 
semiquantitative microscopic analysis while considering 
the number of stained cells and signal intensity. Staining 
of both MAP17 and phospho-g-H2AX was performed. 
In both cases, the score obtained by the intensity levels 
(0, 1, 2 or 3) in positive cells was used. For MAP17, the 
threshold used was the score of the total cohort obtained 
by the ROC curve as the most relevant to establish as a 
dichotomous variable (0.75). For phospho-g-H2AX, there 
was no staining in any of the non-tumor surrounding 
tissue, and t positivity was considered when a positive 
nucleus was observed in the tumor. Immunostaining 
was evaluated through a double-blind visual assessment 
using microscopic observation according to the 
anatomopathological experience of the pathologists.
Cell lines
Characteristics of the cell lines used are shown in 
Supplementary Table 2. All cell lines were authenticated 
and regularly tested for mycoplasma. 
Validation of the response to different doses of 
radiotherapy
We used the clonogenic assay, which enables the 
assessment of differences in reproductive viability (capacity 
of cells to produce progeny, i.e., a single cell to form a 
colony of 50 or more cells) between control untreated cells 
and cells that have undergone exposure to ionizing radiation 
treatment. This method uses the Linear Quadratic model 
to predict the response of a tumor and normal tissues in 
the clinic. When the confluence reached approximately 
90%, cells were irradiated with 2, 4, 6, or 8 Gy using a 
137 Cesium source. After irradiation (24–72 h), the number 
of cells in each sample was counted carefully using a 
hemocytometer and diluted such that an appropriate cell 
number (500–1000) was seeded onto 10-cm dishes. The 
cells were then incubated from 1 to 4 weeks depending on 
the cell line and fixed. ImageJ (Fiji Version 1.44a) was used 
to count colonies. Efficiency and survival fraction were 
calculated as follows: (number of colonies counted /number 
of cells plated)/plating efficiency. SF was expressed as SF 
at 2 Gy if available for comparison to human doses.
Cytotoxicity studies
Cytotoxicity studies were performed as previously 
described. Briefly, 3,000 cells/well were seeded onto 96-
well plates and allowed to attach and grow for 24 h before 
treatment. The drugs were diluted with DMSO or water. 
From here, a “mother plate” was prepared at 200X the 
final concentration in culture for serial dilutions. Serial 
dilutions of each drug from an initial 30 µM dose were 
assayed in a minimum of three independent experiments. 
The medium was removed from the cells and replaced 
with 0.2 ml of medium containing the drug to be tested. 
Each concentration was assayed in triplicate. Two sets 
of control wells were included on each plate, which 
consisted of either medium only or medium with the 
same concentration of DMSO or water. A third control 
set consisting of untreated cells just before drug addition 
was also established, which served as the seeding control 
indicating the number of cells starting the culture. The 
cells were exposed to the drug for 96 h and subsequently 
fixed with glutaraldehyde (0.5%) and stained with crystal 
violet. After dissolving in 20% acetic acid, the resulting 
absorbance was measured at 595 nM using a microplate 
reader (Bio-Rad, Hercules, CA, USA), and the cytotoxic 
effect of each treatment was assessed by calculating the 
concentration necessary to induce 50% cell death (IC50 
value) using PRISM software.
Public databases of clinical samples
To validate our results, we obtained data from 
publicly available clinical and genomic information from 
Oncomine (https://powertools.oncomine.com) and TCGA 
Research Network (https://cancergenome.nih.gov/). 
Statistics
In vitro data are presented as the mean ± standard 
deviation to indicate variation within each group. 
Statistical analysis was performed with the SPSS statistical 
package (v19, IBM). The in vitro and in vivo experiments 
were analyzed using an unpaired non-parametric Mann–
Whitney U test or Student´s t tests. P-values less than 0.05 
were considered significant. The Kaplan-Meier method 
was used for survival analyses of the clinical data and cell 
line xenograft experiments. A Cox proportional hazards 
model was used to adjust for explanatory variables and 
p-values were obtained. Type II ANOVA was used to 
analyze differences in survival among groups. The Cox 
proportional hazards model was used to obtain the hazard 
ratio values.
Variable definitions
DFS was defined as the time from surgery to the 
time the patient experienced any event (local or distant 
recurrence and death). OS was defined as the time from 
surgery to the time the patient died from any cause. 
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